#Hong Kong #Immunotherapy #Akeso #Cadonilimab

Akeso's Breakthrough in Colon Cancer Treatment: Cadonilimab

On October 10, 2026, Akeso, Inc. announced a major milestone with the first patient dosed in a Phase III clinical trial assessing cadonilimab, a groundbreaking PD-1/CTLA-4 bispecific antibody. This trial, aptly named COMPASSION-40/AK104-313, focuses on patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colon cancer who can still undergo surgery.

Cadonilimab, which is designed as a monotherapy for perioperative treatment, aims to establish a new standard for this patient group, which has previously received limited benefits from existing therapies, including conventional chemotherapy. Encouragingly, traditional perioperative chemotherapy for these patients has shown a meager pathological response rate of approximately 7%, underscoring a critical gap in effective treatment options.

What makes cadonilimab unique is its dual action mechanism, targeting both PD-1 and CTLA-4 pathways. This innovative approach hopes to activate and sustain better immune responses against tumors, leading to increased rates of major pathological responses (MPR) and potential reductions in postoperative recurrence. This is particularly significant as MSI-H/dMMR colon cancers have demonstrated high responsiveness to immunotherapy due to their elevated tumor mutational burden and inflamed immune microenvironment.

Previously presented data from a Phase II study of cadonilimab showcased an impressive pathological complete response (pCR) rate of 84.6% among patients who underwent surgery, alongside a 100% MPR rate. Such results are indicative of the drug's potential effectiveness, enhancing its value in cancer treatment landscapes, which often remain rife with unmet medical needs.

Cadonilimab is not Akeso's only endeavor in the battlefield against cancer. The company is steadily expanding the therapeutic applications of this first-in-class bispecific antibody beyond colon cancer, having already received approvals for its use in other cancer types, including gastric, lung, and cervical cancers. It is currently under investigation in thirteen Phase III/registrational studies globally, cementing its foothold in the immuno-oncology (IO) 2.0 space.

The growing incidence and mortality rates associated with colorectal cancer necessitate urgent advancements in treatment, particularly for subset populations that are currently underserved. The initiation of this Phase III trial is promising, as it offers hope for improved long-term outcomes and a chance to advance the treatment landscape for patients with localized MSI-H/dMMR colon cancer.

As the clinical landscape continuously evolves, cadonilimab's prospective ability to shift the paradigm for colorectal cancer treatment is crucial. The drug represents a pathway to transform patient care, challenging existing norms and harnessing the power of immune system engagement.

In conclusion, Akeso is poised to make a substantial impact within the space of cancer treatment—especially as initial results from cadonilimab's earlier trials have garnered considerable attention. As they move forward with the Phase III clinical trial, the biopharmaceutical company remains committed to bringing innovative therapies to the forefront, addressing the needs of patients navigating the challenges of cancer treatment.

For industry observers and stakeholders, Akeso's developments are a noteworthy testament to the evolving nature of cancer therapies that integrate immuno-oncology strategies. As more patients participate in trials like COMPASSION-40, the future of cancer treatment could be marked by breakthrough discoveries and improved survival rates for various malignancies, including colon cancer.